Background: In many clinical trials designed to assess the efficacy of anticancer treatments, overallsurvival (OS) is often used as a primary endpoint despite its several points of weakness.Methods: This study evaluated the role of progression-free survival (PFS) in the first threelines of treatment as a potential surrogate endpoint of OS in patients with metastatic colorectalcancer (MCRC). One hundred and twenty patients with MCRC were enrolled in this study. Themedian PFS of the first-, second-, and third-lines of treatment and the OS were evaluated. Thecorrelation between the time to progression and the OS was analyzed. The median PFS of thethree lines of treatment were 8.5, 5, and 3 months, respectively.Results: The median OS was 32.4 months. A modest correlation was found between the PFSto the first-line treatment with Folfox–avastin and OS. Similar data were obtained with thesecond-line treatment. However, no correlation was found between the PFS and OS during thethird-line treatment. The regression analysis revealed that PFS is predictive of OS.Conclusion: In brief, the PFS of the first- and second-lines of treatment could be a good candidate as a surrogate endpoint of OS in patients with MCRC.
|Numero di pagine||5|
|Rivista||OncoTargets and Therapy|
|Stato di pubblicazione||Published - 2018|
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)